Recombinant Human TNFSF14 protein, Mouse IgG2a Fc-tagged, low endotoxin
Cat.No. : | TNFSF14-394H |
Product Overview : | Recombinant Human TNFSF14 protein (Asp74-Val240), fused to Mouse IgG2a Fc tag at N-terminus, was expressed in human 293 cells (HEK293). |
- Specification
- Gene Information
- Related Products
Description : | Tumor necrosis factor ligand superfamily member 14(LIGHT) is a tumor necrosis factor (TNF) superfamily ligand that regulates T cell immune responses by signaling through the herpes virus entry mediator (HVEM) and the lymphotoxin beta receptor (LTbetaR). LIGHT has emerged as a potent initiator of T cell co-stimulation signals effecting CTL-mediated tumor rejection, allograft rejection and graft versus host disease. Constitutive expression of LIGHT leads to tissue destruction and autoimmune-like disease syndromes. |
Source : | HEK293 |
Species : | Human |
Tag : | Mouse IgG2a Fc |
Form : | Lyophilized from 0.22 um filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5, 10% trehalose. |
Molecular Mass : | The protein has a calculated MW of 45.1 kDa. The protein migrates as 50 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation. |
Protein length : | 167 |
Endotoxin : | Less than 0.1 EU per ug by the LAL method. |
Purity : | >95% as determined by SDS-PAGE. |
Storage : | For long term storage, the product should be stored at lyophilized state at -20 centigrade or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at: -20 centigrade to -70 centigrade for 12 months in lyophilized state; -70 centigrade for 3 months under sterile conditions after reconstitution. |
Reconstitution : | It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4℃ before opening to recover the entire contents. |
Gene Name : | TNFSF14 |
Official Symbol : | TNFSF14 |
Synonyms : | TNFSF14; tumor necrosis factor (ligand) superfamily, member 14; tumor necrosis factor ligand superfamily member 14; CD258; HVEM L; LIGHT; LTg; delta transmembrane LIGHT; herpesvirus entry mediator A; herpesvirus entry mediator ligand; herpesvirus entry mediator-ligand; herpes virus entry mediator ligand; ligand for herpesvirus entry mediator; tumor necrosis factor receptor-like 2; tumor necrosis factor superfamily member LIGHT; TR2; HVEML |
Gene ID : | 8740 |
mRNA Refseq : | NM_003807 |
Protein Refseq : | NP_003798 |
MIM : | 604520 |
UniProt ID : | O43557 |
Products Types
◆ Recombinant Protein | ||
TNFSF14-1324H | Acitve Recombinant Human TNFSF14 protein(Asp74-Val240), rFc-tagged | +Inquiry |
TNFSF14-9484M | Recombinant Mouse TNFSF14 Protein, His (Fc)-Avi-tagged | +Inquiry |
Tnfsf14-147M | Recombinant Mouse Tnfsf14 Protein | +Inquiry |
TNFSF14-1544M | Recombinant Mouse TNFSF14 Protein, His-tagged | +Inquiry |
TNFSF14-288H | Recombinant Human TNFSF14 Protein, MYC/DDK-tagged, C13 and N15-labeled | +Inquiry |
◆ Lysates | ||
TNFSF14-891HCL | Recombinant Human TNFSF14 293 Cell Lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (7)
Ask a questionTNFSF14, when delivered to or expressed within tumors, causes significant changes primarily through vascular normalization and generation of tertiary lymphoid structures.
While investigators have used multiple vectors to deliver TNFSF14 to tumor tissues, there are still improvements needed, and components within the human tumor microenvironment may impede translational efforts.
TNFSF14 stands for Tumor Necrosis Factor Superfamily Member 14.
TNFSF14's changes in the tumor microenvironment can synergize with methods inducing anti-tumor immune responses, such as checkpoint inhibitors and tumor vaccines, improving immunotherapeutic strategies against cancer.
TNFSF14 has been used in multiple tumor models, where it can be combined with other immunotherapy modalities to clear established solid tumors and treat metastatic events.
TNFSF14 has been in pre-clinical development for over a decade.
TNFSF14 shows promise in enhancing treatment approaches in cancer immunotherapy.
Customer Reviews (3)
Write a reviewThe extended longevity of results gave us the confidence to delve deeper into complex biological processes.
It was reassuring to know that the product's effects persisted, allowing for thorough and comprehensive research.
The ability to obtain enduring results positively influenced the depth of our investigations.
Ask a Question for All TNFSF14 Products
Required fields are marked with *
My Review for All TNFSF14 Products
Required fields are marked with *
Inquiry Basket